Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial - Goldberg, SB; Gettinger, SN; Mahajan, A (Lancet Oncol, 2016)
et al.